巴西科兴新冠疫苗接种者中两例接种后感染 P1 变异株的 SARS-CoV-2 病例研究。
Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.
机构信息
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil.
Hospital de Base, São José do Rio Preto, São Paulo 15090-000, Brazil.
出版信息
Viruses. 2021 Jun 26;13(7):1237. doi: 10.3390/v13071237.
The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.
有效的 COVID-19 疫苗和安全疫苗的快速发展对于减轻严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）的传播起到了重要作用。此外，SARS-CoV-2 变体的出现引起了人们对这些疫苗效力的担忧。在此，我们报告了两例接种科兴疫苗后感染 P1 变体的突破性感染病例，科兴疫苗是巴西免疫计划中紧急使用授权的两种疫苗之一。我们的观察结果表明，该疫苗降低了疾病的严重程度，并强调了接种疫苗后感染 P1 变体以及继续努力预防和诊断接种者感染的潜在风险。
Zotero 插件